Objective To investigate the preoperative prediction of the expression level of programmed cell death ligand 1(PD-L1)in non-small cell lung cancer(NSCLC)by a nomogram model constructed with clinical data,conventional CT signs and spectral CT parameters.Methods A retrospective analysis was conducted on 52 patients with pathologically confirmed NSCLC and undergoing preoperative spectral CT examination.The patients were categorized into positive and negative groups according to PD-L1 expression level,and their clinical data,conventional CT signs and spectral CT parameters were collected.Specifically,clinical data included gender,age,Ki-67 and tumor markers;conventional CT signs included tumor density,margins,calcification,spiculation,lobulation,pleural indentation and cavitation;and spectral CT parameters measured in the arterial and venous phases included effective atomic number(Eff-Z),iodine concentration(IC),water concentration(WC)and normalized iodine concentration(NIC).Intergroup differences were analyzed,and multivariate Logistic regression was used to identify independent predictors and establish the prediction model which was evaluated for prediction performance and accuracy using receiver operating characteristic(ROC)curves,calibration curve and decision curve analyses.Results For clinical data,only the difference in gender between two groups had statistical significance(P<0.05).The spectral CT parameters(IC,NIC and Eff-Z)in the arterial and venous phases of PD-L1 positive group were all greater than those of PD-L1 negative group,with statistically significant differences(P<0.05).Multivariate Logistic regression analysis identified gender(P=0.024),venous-phase Eff-Z(P=0.002),and venous-phase IC(P=0.003)as independent predictive factors for PD-L1 expression.The nomogram prediction model constructed with these independent predictors had an area under curve of 0.80,a sensitivity of 88.00%,and a specificity of 59.00%.The calibration curve showed that the predicted values had a high consistency with the actual values.The decision curve revealed that when the high-risk threshold was between 0.10 and 0.83,the model could achieve the maximum net benefit.Conclusion The nomogram model constructed with spectral CT parameters and clinical data has certain value in predicting the expression level of PD-L1 in NSCLC.

With the rapid development of genomics and biotechnology,forensic biogeographical ancestry inference-a technique for determining an individual's population origin through the detection of ancestry informative genetic markers-has emerged as a critical research domain in forensic genetics.As a pivotal method for individual identity identification,forensic ancestry inference provides crucial investigative leads and scientific evidence for case resolution and judicial proceedings.This review comprehensively examines the genetic markers,analytical methodologies,current challenges,and developmental trajectories of forensic ancestry inference.

With the rapid development of genomics and biotechnology,forensic biogeographical ancestry inference-a technique for determining an individual's population origin through the detection of ancestry informative genetic markers-has emerged as a critical research domain in forensic genetics.As a pivotal method for individual identity identification,forensic ancestry inference provides crucial investigative leads and scientific evidence for case resolution and judicial proceedings.This review comprehensively examines the genetic markers,analytical methodologies,current challenges,and developmental trajectories of forensic ancestry inference.

Objective To investigate the preoperative prediction of the expression level of programmed cell death ligand 1(PD-L1)in non-small cell lung cancer(NSCLC)by a nomogram model constructed with clinical data,conventional CT signs and spectral CT parameters.Methods A retrospective analysis was conducted on 52 patients with pathologically confirmed NSCLC and undergoing preoperative spectral CT examination.The patients were categorized into positive and negative groups according to PD-L1 expression level,and their clinical data,conventional CT signs and spectral CT parameters were collected.Specifically,clinical data included gender,age,Ki-67 and tumor markers;conventional CT signs included tumor density,margins,calcification,spiculation,lobulation,pleural indentation and cavitation;and spectral CT parameters measured in the arterial and venous phases included effective atomic number(Eff-Z),iodine concentration(IC),water concentration(WC)and normalized iodine concentration(NIC).Intergroup differences were analyzed,and multivariate Logistic regression was used to identify independent predictors and establish the prediction model which was evaluated for prediction performance and accuracy using receiver operating characteristic(ROC)curves,calibration curve and decision curve analyses.Results For clinical data,only the difference in gender between two groups had statistical significance(P<0.05).The spectral CT parameters(IC,NIC and Eff-Z)in the arterial and venous phases of PD-L1 positive group were all greater than those of PD-L1 negative group,with statistically significant differences(P<0.05).Multivariate Logistic regression analysis identified gender(P=0.024),venous-phase Eff-Z(P=0.002),and venous-phase IC(P=0.003)as independent predictive factors for PD-L1 expression.The nomogram prediction model constructed with these independent predictors had an area under curve of 0.80,a sensitivity of 88.00%,and a specificity of 59.00%.The calibration curve showed that the predicted values had a high consistency with the actual values.The decision curve revealed that when the high-risk threshold was between 0.10 and 0.83,the model could achieve the maximum net benefit.Conclusion The nomogram model constructed with spectral CT parameters and clinical data has certain value in predicting the expression level of PD-L1 in NSCLC.

Objective:To investigate the sensitivity of tumor organoids derived from samples of colorectal cancer to lobaplatin and oxaliplatin hyperthermic perfusion in vitro and to assist clinical development of hyperthermic intraperitoneal chemotherapy. Method:Tumor samples and relevant clinical data were collected from patients with pathologically confirmed colorectal cancer in the Sixth Affiliated Hospital of Sun Yat-sen University from July 2021 to December 2022. Organoids were cultured and tumor tissue were passaged. In vitro hyperthermic perfusion experiments were performed on organoids with good viability. Firstly, 10 organoids were treated with oxaliplatin and lobaplatin at the following six concentrations: 1 000, 250, 62.5, 15.6, 3.9, and 0.98 μmol/L. The organoids were exposed to oxaliplatin at 42℃ for 30 minutes and to lobaplatin at 42℃ for 60 minutes. Dose-response curves of responses to in vitro hyperthermic perfusion with these two drugs were constructed and evaluated. Clinical doses of oxaliplatin and lobaplatin were further tested on 30 organoids. This testing revealed oxaliplatin was effective at 579 μmol/L at a hyperthermic perfusion temperature of 42℃ for 30 min and lobaplatin was effective at 240 μmol/L at a hyperthermic perfusion temperature of 42℃ for 60 minutes. Result:Thirty-two tumor organoids were cultured from samples of colorectal cancer. The median concentration required for oxaliplatin to eliminate 50% of tumor cells (IC50) was 577.45 μmol/L (IQR: 1846.09 μmol/L). The median IC50 for lobaplatin was 85.04 μmol/L (IQR: 305.01 μmol/L).The difference between the two groups was not statistically significant ( Z=1.784, P=0.084). In seven of 10 organoids, lobaplatin showed a greater IC50 after in vitro hyperthermic perfusion than did oxaliplatin. Testing of 30 organoids with clinical doses of oxaliplatin and lobaplatin revealed that oxaliplatin achieved an average inhibition rate of 39.6% (95%CI: 32.1%?47.0%), whereas the average rate of inhibition for lobaplatin was 89.7% (95%CI: 87.0%?92.3%): this difference is statistically significant ( t=?15.282, P<0.001). Conclusion:The rate of inhibition achieved by hyperthermic perfusion of lobaplatin in vitro is better than that achieved by hyperthermic perfusion with oxaliplatin. Lobaplatin is more effective than oxaliplatin when administered by hyperthermic intraperitoneal perfusion and therefore has the potential to replace oxaliplatin in this setting.

Objective To investigate the effect and mechanism of osteopontin(OPN)in hepatoma cell migration through galectin-3 binding protein(LGALS3BP).Methods Human hepatoma cell lines SMMC-7721,SMMC-P(stably transfected with empty eukaryotic expression vectors),and SMMC-OPN(stably transfected with the OPN gene)were cultured.mRNA expression levels of OPN and LGALS3BP were measured by RT-qPCR.Western blot assays were used to analyze the relative protein expression of OPN and LGALS3BP and PI3K/AKT pathway.Wound healing assays were performed to explore the cell migration ability.After transfection with LGALS3BP-targeting small interfering RNA(si-LGALS3BP)or negative control small RNA(si-NC)into SMMC-OPN cells,cell migration and relative expression of PI3K/AKT pathway-related proteins were assessed.Results Compared with SMMC-7721 and SMMC-P,the migratory ability of SMMC-OPN cells was significantly reinforced,and expression of LGALS3BP was obviously upregulated at both mRNA and protein levels.Moreover,relative expression of p-PI3K/PI3K and p-AKT/AKT proteins was significantly increased.Wound healing assays showed that the si-LGALS3BP obviously suppressed the migratory ability of SMMC-OPN cells.Furthermore,relative expression of p-PI3K/PI3K and p-AKT/AKT proteins in SMMC-OPN cells was significantly decreased after transfection of si-LGALS3BP.Conclusions OPN activates the PI3K/AKT pathway by upregulating LGALS3BP expression to promote hepatoma cell migration.

Objective:To investigate the sensitivity of tumor organoids derived from samples of colorectal cancer to lobaplatin and oxaliplatin hyperthermic perfusion in vitro and to assist clinical development of hyperthermic intraperitoneal chemotherapy. Method:Tumor samples and relevant clinical data were collected from patients with pathologically confirmed colorectal cancer in the Sixth Affiliated Hospital of Sun Yat-sen University from July 2021 to December 2022. Organoids were cultured and tumor tissue were passaged. In vitro hyperthermic perfusion experiments were performed on organoids with good viability. Firstly, 10 organoids were treated with oxaliplatin and lobaplatin at the following six concentrations: 1 000, 250, 62.5, 15.6, 3.9, and 0.98 μmol/L. The organoids were exposed to oxaliplatin at 42℃ for 30 minutes and to lobaplatin at 42℃ for 60 minutes. Dose-response curves of responses to in vitro hyperthermic perfusion with these two drugs were constructed and evaluated. Clinical doses of oxaliplatin and lobaplatin were further tested on 30 organoids. This testing revealed oxaliplatin was effective at 579 μmol/L at a hyperthermic perfusion temperature of 42℃ for 30 min and lobaplatin was effective at 240 μmol/L at a hyperthermic perfusion temperature of 42℃ for 60 minutes. Result:Thirty-two tumor organoids were cultured from samples of colorectal cancer. The median concentration required for oxaliplatin to eliminate 50% of tumor cells (IC50) was 577.45 μmol/L (IQR: 1846.09 μmol/L). The median IC50 for lobaplatin was 85.04 μmol/L (IQR: 305.01 μmol/L).The difference between the two groups was not statistically significant ( Z=1.784, P=0.084). In seven of 10 organoids, lobaplatin showed a greater IC50 after in vitro hyperthermic perfusion than did oxaliplatin. Testing of 30 organoids with clinical doses of oxaliplatin and lobaplatin revealed that oxaliplatin achieved an average inhibition rate of 39.6% (95%CI: 32.1%?47.0%), whereas the average rate of inhibition for lobaplatin was 89.7% (95%CI: 87.0%?92.3%): this difference is statistically significant ( t=?15.282, P<0.001). Conclusion:The rate of inhibition achieved by hyperthermic perfusion of lobaplatin in vitro is better than that achieved by hyperthermic perfusion with oxaliplatin. Lobaplatin is more effective than oxaliplatin when administered by hyperthermic intraperitoneal perfusion and therefore has the potential to replace oxaliplatin in this setting.

【Objective】 To study the current situation of apheresis platelets collection in various regions of Gansu province by comparing and analyzing relevant data from blood stations in 14 prefecture-level cities of Gansu province. 【Methods】 The units of collected platelets and rate of double-dose collection in 13 regional blood stations and 1 provincial blood center from 2016 to 2020, as well as the clinical supply and demand was statistically analyzed. 【Results】 From 2016 to 2020, the total units of platelets collected by 13 blood stations and 1 blood center in Gansu increased from 11 255 U to 15 270 U, with the increase rate at 35.7% in 5 years, and mainly were collected by the provincial blood center (74.57%, 50 253/ 67 392). Although the rate of double-dose collection in the province showed a steady upward trend, only 3 blood stations realized annual double-dose collection more than 20%. There was still a gap of about 10% between supply and clinical needs. 【Conclusion】 Although the number of platelet collections and units in each blood station in Gansu is on the rise in general, the units collected varies in each blood station. Therefore, further measures need to be taken from the aspects of publicity, recruitment, optimizing the collection process, improving the rate of double-dose collection, retention of regular blood donors and regional coordination to increase the collection units, narrow down the regional gap and ensure the balance between supply and demand.

Objective To investigate the effects of dexmedetomidine on oxidative stress response after operation in patients with acute craniocerebral trauma. Methods Sixty patients who underwent intracranial hematoma and decompressive craniectomy within 24 h after acute craniocerebral trauma,were randomly divided into midazolam group and dexmedetomidine group(n=30). All patients were maintained seda-tion for 12 h after operation. Mean arterial blood pressure (MAP),heart rate (HR),blood glucose,S-100B protein (S-100B),malond-ia1ehyde(MDA) and superoxide dismutase (SOD) were recorded at the end of operation(T0),3 h(T1),6 h(T2),12 h(T3) after opera-tion. Results Postoperative MAP, HR and blood glucose were stability in two groups. MAP, HR and blood glucose of dexmedetomidine group were lower than those of midazolam group(P<0. 05). The serum concentrations of S-100B and MDA gradually reduced,and the serum levels of SOD gradually increased at T1 ~T3 in two groups. Compared with midazolam group, these changes were significantly higher in dexmedetomidine group(P<0. 05). Conclusion Dexmedetomidine can protect the brain by maintaining haemodynamic stability and attenu-ating oxidative stress response after operation in patients with acute craniocerebral trauma.